Atezolizumab monotherapy as first-line treatment for non-small cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a cost-effectiveness analysis in the USA
The IMpower-110, an open-label, randomised, phase 3 clinical trial (NCT02409342). The IPSOS clinical trial (NCT03191786).
Authors
- Ding‐Chao Rong (ORCID: https://orcid.org/0009-0002-8414-7845)
- Hui Lin (ORCID: https://orcid.org/0000-0001-9785-2098)
- B.T. Li (ORCID: https://orcid.org/0009-0000-6292-2244)
Institutions
- Shaoyang University (CN)
- Third Affiliated Hospital of Southern Medical University (CN)
- The Central Hospital of Shaoyang (CN)
- Guangdong Provincial People's Hospital (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- BMJ Open
- Published
- 2024-11-01
- DOI
- https://doi.org/10.1136/bmjopen-2023-083716
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00